Evidence map›Paper›PMID 28910526›Full record

ReviewAmerican journal of medical genetics. Part C, Seminars in medical genetics2017

Genetic rodent models of brain disorders: Perspectives on experimental approaches and therapeutic strategies.

Christopher M McGraw, Christopher S Ward, Rodney C Samaco

Abstract readReview
In one paragraph

Review in American journal of medical genetics. Part C, Seminars in medical genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Rigor and reproducibility in rodent behavioral research.Neurobiology of learning and memory · 2019
    Review
  15. Genetic rodent models of brain disorders: Perspectives on experimental approaches and therapeutic strategies.American journal of medical genetics. Part C, Seminars in medical genetics · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christopher M McGrawDepartment of Neurology, University of California, San Francisco, San Francisco, California.
Christopher S WardJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas.
Rodney C SamacoJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas.ORCID 0000-0001-5636-5314

Funding

Steps towards a paternal gene activation therapy for Angelman syndromeU54HD083092 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI NELSON, DAVID LOREN, SAMACO, RODNEY C · 2014 to 2019
$7.8M
PROGRAM IN HUMAN MOLECULAR GENETICST32GM008307 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI SHAULSKY, GAD · 1990 to 2020
$6.6M
Neurobehavioral and biochemical outcome measures in Rett syndrome rodent modelsR01HD083181 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI NEUL, JEFFREY L, SAMACO, RODNEY C · 2016 to 2020
$3.0M
THE GENETIC AND NEUROANATOMICAL ORIGIN OF SOCIAL BEHAVIORDP5OD009134 · OD · BAYLOR COLLEGE OF MEDICINE · PI SAMACO, RODNEY C · 2011 to 2015
$2.0M
NICHD NIH HHS R01 HD083181NICHD NIH HHS U54 HD083092NIGMS NIH HHS T32 GM008307NIH HHS DP5 OD009134
6 · The paper itself

Abstract

Neurobehavioral disorders comprised of neurodegenerative, neurodevelopmental, and psychiatric disorders together represent leading causes of morbidity and mortality. Despite significant academic research and industry efforts to elucidate the disease mechanisms operative in these disorders and to develop mechanism-based therapies, our understanding remains incomplete and our access to tractable therapeutic interventions severely limited. The magnitude of these short-comings can be measured by the growing list of disappointing clinical trials based on initially promising compounds identified in genetic animal models. This review and commentary will explore why this may be so, focusing on the central role that genetic models of neurobehavioral disorders have come to occupy in current efforts to identify disease mechanisms and therapies. In particular, we will highlight the unique pitfalls and challenges that have hampered success in these models as compared to genetic models of non-neurological diseases as well as to symptom-based models of the early 20th century that led to the discovery of all major classes of psychoactive pharmaceutical compounds still used today. Using examples from specific genetic rodent models of human neurobehavioral disorders, we will highlight issues of reproducibility, construct validity, and translational relevance in the hopes that these examples will be instructive toward greater success in future endeavors. Lastly, we will champion a two-pronged approach toward identifying novel therapies for neurobehavioral disorders that makes greater use of the historically more successful symptom-based approaches in addition to more mechanism-based approaches.

Indexed as

Disease Models, AnimalAnimalsBrain DiseasesGenetic Predisposition to DiseaseHeredodegenerative Disorders, Nervous SystemHumansMental DisordersMiceNeurodevelopmental Disordersbehavioral geneticsbehavioral neuroscienceCNS disorderspreclinicalrodent models

Identifiers

PMID28910526
PMCPMC5659732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.